ALX Stock Recent News
ALX LATEST HEADLINES
ALX, HAFC and FFBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 28, 2025.
Magnifying the trend of positive earnings estimate revisions for these highly ranked stocks is their attractive dividends, which are reassuring as investors hope the broader market will continue to stabilize and rebound.
ALX, HAFC and HBNC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 25, 2025.
Here is how Alexander's (ALX) and Banco Bilbao (BBVA) have performed compared to their sector so far this year.
ALX, HAFC and FHB made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 13, 2025.
ALX, VLY and HAFC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 11, 2025.
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. PT/9:00 a.m.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m.